Exploring an Integrative Therapy for Treating COVID-19:A Randomized Controlled Trial

作     者：WANG Jia-bo WANG Zhong-xia JING Jing ZHAO Peng DONG Jing-hui ZHOU Yong-feng YANG Guang NIU Ming ZHAO Xu JIANG Tian-jun Bl Jing-feng XU Zhe ZHANG Ping WU Dan BAI Zhao-fang GUO Yu-ming YU Si-miao SUN Yong-qiang ZHANG Zi-teng ZHAN Xiao-yan LI Peng-yan DING Jin-biao ZHAO Peng-fei SONG Xue-ai TANG Jian-yuan HE Dong-chu CHEN Zhu QIN En-qiang WANG Rui-lin XIAO Xiao-he WANG Jia-bo;WANG Zhong-xia;JING Jing;ZHAO Peng;DONG Jing-hui;ZHOU Yong-feng;YANG Guang;NIU Ming;ZHAO Xu;JIANG Tian-jun;BI Jing-feng;XU Zhe;ZHANG Ping;WU Dan;BAI Zhao-fang;GUO Yu-ming;YU Si-miao;SUN Yong-qiang;ZHANG Zi-teng;ZHAN Xiao-yan;LI Peng-yan;DING Jin-biao;ZHAO Peng-fei;SONG Xue-ai;TANG Jian-yuan;HE Dong-chu;CHEN Zhu;QIN En-qiang;WANG Rui-lin;XIAO Xiao-he

作者机构：China Military Institute of Chinese MedicineThe Fifth Medical Center of Chinese PLA General HospitalBeijing(100039)China Integrative Medical CenterThe Fifth Medical Center of Chinese PLA General HospitalBeijing(100039)China Treatment and Research Center for Infectious DiseasesThe Fifth Medical Center of Chinese PLA General HospitalBeijing(100039)China National Clinical Research Center for Infectious DiseasesBeijing(100039)China Department of RadiologyThe Fifth Medical Center of Chinese PLA General HospitalBeijing(100039)China Research Center for Clinical and Translational MedicineThe Fifth Medical Center of Chinese PLA General HospitalBeijing(100039)China Sichuan Evidence-Based Medicine Center of Traditional Chinese Medicine Affliated HospitalChengdu University of Traditional Chinese MedicineChengdu(610075)China College of Life ScienceBeijing University of Chinese MedicineBeijing(100029)China Department of Integrated TreatmentGeneral Hospital of Central Theater CommandWuhan(430070)China 

出 版 物：《Chinese Journal of Integrative Medicine》 (中国结合医学杂志（英文版）)

年 卷 期：2020年第26卷第9期

页      面：648-655页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 1005[医学-中医学] 1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：the National Administration of Traditional Chinese Medicine Project(No.2020ZYLCYJ05-1) the National Natural Science Foundation of China(Nos.81630100,81721002,81930110) China PLA Biosecurity Project(No.19SWAQ13) China PLA Emergency Project(BWS20J006) the Beijing Administration of Traditional Chinese Medicine Project(Nos.YJ2020-03,SYFY202011) 

主　　题：COVID-19 SARS-CoV-2 acute respiratory distress syndrome Chinese medicine 

摘      要：Objectives:To develop a new Chinese medicine(CM)-based drug and to evaluate its safety and effect for suppressing acute respiratory distress syndrome(ARDS)in COVID-19 ***:A putative ARDS-suppressing drug Keguan-1 was first developed and then evaluated by a randomized,controlled two-arm *** two arms of the trial consist of a control therapy(alpha interferon inhalation,50(x g twice daily;and lopinavir/ritonavir,400 and 100 mg twice daily,respectively)and a testing therapy(control therapy plus Keguan-119.4 g twice daily)by random number table at 1:1 ratio with 24 cases each *** 2-week treatment,adverse events,time to fever resolution,ARDS development,and lung injury on newly diagnosed COVID-19 patients were ***:An analysis of the data from the first 30 participants showed that the control arm and the testing arm did not exhibit any significant differences in terms of adverse *** on this result,the study was expanded to include a total of 48 participants(24 cases each arm).The results show that compared with the control arm,the testing arm exhibited a significant improvement in time to fever resolution(P=0.035),and a significant reduction in the development of ARDS(P=0.048).Conclusions:Keguan-1-based integrative therapy was safe and superior to the standard therapy in suppressing the development of ARDS in COVID-19 patients.(Trial registration *** 04251871 at ***).